Oct 14, 2021
On August 24, 2021, ICER released a revised version of a final evidence report from 2018 evaluating the clinical and cost effectiveness of three emerging treatments for hereditary angioedema. Unfortunately, while ICER tried to update its analysis — supposedly to...
Sep 27, 2021
On August 18, 2021, ICER released its draft evidence report, “Tezepelumab for Severe Asthma: Effectiveness and Value.” This is the first step in ICER’s standard process that – after a period of public comment – will result in the release of final evidence report,...
Sep 1, 2021
On August 18, 2021, ICER released its draft evidence report, “Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value.” This is the first step in ICER’s process that, if the announced schedule holds, will lead to the release of final evidence report in...
Aug 23, 2021
On August 17, 2021, ICER issued a Final Evidence Report on the clinical and cost-effectiveness of new treatments for atopic dermatitis (more commonly referred to as eczema). After following its typical process for gathering and reviewing data, ICER concluded that the...
Aug 5, 2021
On August 5, 2021, ICER issued its Final Evidence Report on aducanumab, a first-of-its-kind medication created to treat Alzheimer’s disease. Following its typical process for gathering information – which included the solicitation of public comments and a public...
Jul 26, 2021
By Robert Popovian & Mark Atalla July 16, 2021 Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003. While there has been significant discussion about aducanumab’s...
